Anzeige
Meldung des Tages: Goldaktie mit Nachholpotenzial: Über 2 Mio. Unzen Gold – und trotzdem erst 59 Mio. USD Börsenwert?

Lucid Diagnostics Aktie News

Aktie
WKN:  ISIN:  US54948X1090 US-Symbol:  LUCD Branche:  Gesundheitswesen: Ausstattung u. Produkte Land:  USA
1,19 $
+0,05 $
+4,39%
1,0042 € 21:59:59 Uhr
Depot/Watchlist
Marktkapitalisierung *
-
Streubesitz
36,90%
KGV
-2,43
Index-Zuordnung
-

Lucid Diagnostics News

30.07.25 - PR Newswire
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 13, 2025
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 13, 2025 PR Newswire
16.07.25 - PR Newswire
MolDX to Convene Expert Medical Panel on Medicare Local Coverage Determination (LCD) for Lucid Diagnostics' EsoGuard® Esophageal DNA Test
MolDX to Convene Expert Medical Panel on Medicare Local Coverage Determination (LCD) for Lucid Diagnostics' EsoGuard® Esophageal DNA Test PR Newswire
18.06.25 - PR Newswire
Major California Health System Launches Comprehensive Esophageal Precancer Testing Program Using Lucid Diagnostics' EsoGuard® Esophageal DNA Test
Major California Health System Launches Comprehensive Esophageal Precancer Testing Program Using Lucid Diagnostics' EsoGuard® Esophageal DNA Test PR Newswire
27.05.25 - PR Newswire
Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes
Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes PR Newswire
15.05.25 - PR Newswire
PAVmed Provides Business Update and Reports First Quarter 2025 Financial Results
PAVmed Provides Business Update and Reports First Quarter 2025 Financial Results PR Newswire
14.05.25 - PR Newswire
Lucid Diagnostics Provides Business Update and Reports First Quarter 2025 Financial Results
Lucid Diagnostics Provides Business Update and Reports First Quarter 2025 Financial Results PR Newswire
01.05.25 - PR Newswire
PAVmed to Hold a Business Update Conference Call and Webcast on May 15, 2025
PAVmed to Hold a Business Update Conference Call and Webcast on May 15, 2025 PR Newswire
30.04.25 - PR Newswire
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025 PR Newswire
24.04.25 - PR Newswire
NCI-Sponsored Study Shows Positive Data for Lucid Diagnostics' EsoGuard® Esophageal DNA Test in Patients Without Symptomatic GERD
NCI-​Sponsored Study Shows Positive Data for Lucid Diagnostics' EsoGuard® Esophageal DNA Test in Patients Without Symptomatic GERD PR Newswire
11.04.25 - PR Newswire
Lucid Diagnostics Announces Closing of Public Offering of Common Stock
Lucid Diagnostics Announces Closing of Public Offering of Common Stock PR Newswire
09.04.25 - PR Newswire
Lucid Diagnostics Announces Pricing of Public Offering of Common Stock
Lucid Diagnostics Announces Pricing of Public Offering of Common Stock PR Newswire
09.04.25 - PR Newswire
Lucid Diagnostics Announces Proposed Public Offering of Common Stock
Lucid Diagnostics Announces Proposed Public Offering of Common Stock PR Newswire
03.04.25 - PR Newswire
Lucid Diagnostics to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
Lucid Diagnostics to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference PR Newswire
27.03.25 - PR Newswire
Lucid Diagnostics Launches "Embrace the Future" Campaign Showcasing EsoCheck's Groundbreaking Collect+Protect Esophageal Cell Collection Technology
Lucid Diagnostics Launches "Embrace the Future" Campaign Showcasing EsoCheck's Groundbreaking Collect+Protect Esophageal Cell Collection Technology PR Newswire
24.03.25 - PR Newswire
Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results PR Newswire
20.03.25 - PR Newswire
Lucid Diagnostics Announces Updated National Comprehensive Cancer Network® (NCCN) Guidelines Now Include Esophageal Precancer Screening
Lucid Diagnostics Announces Updated National Comprehensive Cancer Network® (NCCN) Guidelines Now Include Esophageal Precancer Screening PR Newswire
18.03.25 - PR Newswire
Lucid Diagnostics' ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication
Lucid Diagnostics' ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-​Reviewed Publication PR Newswire
10.03.25 - PR Newswire
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 24, 2025
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 24, 2025 PR Newswire
05.03.25 - PR Newswire
Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering
Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering PR Newswire
04.03.25 - PR Newswire
Lucid Diagnostics Announces $15.3 Million Registered Direct Offering
Lucid Diagnostics Announces $15.3 Million Registered Direct Offering PR Newswire

Newssuche

Videos

newspaper
29.01.26 -9,63%
Rekordjagd bei Gold! Februar Ausblick & Forecast
Ab 2.2. (Montag) börsentäglich um 18 Uhr FEIERABEND-​TRADING. Echte Trades, strategiebasiert, ... Mehr »
Anzeige

Aktie im Fokus

Durchbruch bei Drohnen-Batterien
NEO Battery Materials Ltd
0,39 €
-3,94%
NEO Battery Materials Ltd Chart
Diese Nachricht schockt den Markt
Mehr zur Aktie »